Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229 doi: 10.1186/ar2669

Xiang YJ, Dai SM (2009) Prevalence of rheumatic diseases and disability in China. Rheumatol Int 29:481–490 doi: 10.1007/s00296-008-0809-z

Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916 doi: 10.1056/NEJM200103223441207

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324 doi: 10.1002/art.1780310302

Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588 doi: 10.1136/ard.2010.138461

Combe B, Landewe R, Lukas C et al (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34–45 doi: 10.1136/ard.2005.044354

Lard LR, Visser H, Speyer I et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446–451 doi: 10.1016/S0002-9343(01)00872-5

O’Dell JR (2004) Therapeutic strategies for Rheumatoid arthritis. N Engl J Med 350:2591–2602 doi: 10.1056/NEJMra040226

Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy. Arthritis Rheum 54:26–37 doi: 10.1002/art.21519

St Clair EW, van der Heijde DM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443 doi: 10.1002/art.20568

Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269 doi: 10.1016/S0140-6736(04)16676-2

Poleksic L, Zdravkovic D, Jablanovic D, Watt I, Bacic G (1993) Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography. Skeletal Radiol 22:577–580 doi: 10.1007/BF00197138

Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35:745–757 doi: 10.1016/j.rdc.2009.10.001

Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA (1997) Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 56:463–469 doi: 10.1136/ard.56.8.463

Masdottir B, Jónsson T, Manfredsdottir V, Víkingsson A, Brekkan A, Valdimarsson H (2000) Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 39:1202–1205 doi: 10.1093/rheumatology/39.11.1202

Forslind K, Ahlmén M, Eberhardt K, Hafström I, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095 doi: 10.1136/ard.2003.014233

Möttönen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P (1998) Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with “sawtooth” strategy. Ann Rheum Dis 57:533–539 doi: 10.1136/ard.57.9.533

Richi P, Balsa A, Muñoz-Fernández S et al (2002) Factors related to radiological damage in 61 Spaniards with early rheumatoid arthritis. Ann Rheum Dis 61:270–272 doi: 10.1136/ard.61.3.270

Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907–927 doi: 10.1016/j.berh.2007.05.007

Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784 doi: 10.1002/art.23721

Lillegraven S, Kvien TK (2007) Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:827–840 doi: 10.1016/j.berh.2007.05.004

van der Heijde D, Klareskog L, Boers M et al (2005) Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64:1582–1587 doi: 10.1136/ard.2004.034371

Weinblatt ME, Coblyn JS, Fox DA et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822 doi: 10.1056/NEJM198503283121303

Weinblatt ME, Kaplan H, Germain BF et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492–1498 doi: 10.1002/art.1780371013

Mikuls TR, O’Dell JR (2000) The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 43:464–465 doi: 10.1002/1529-0131(200002)43:2%3C464::AID-ANR30%3E3.0.CO;2-U

Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33:1449–1461 doi: 10.1002/art.1780331001

Boers M, Verhoeven AC, Markusse HM et al (1997) Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318 doi: 10.1016/S0140-6736(97)01300-7

Landewe RB, Boers M, Verhoeven AC et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46:347–356 doi: 10.1002/art.10083

Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681 doi: 10.1016/S0140-6736(04)15640-7

Möttönen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. The Lancet 353:1568–1573 doi: 10.1016/S0140-6736(98)08513-4

Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259 doi: 10.1056/NEJM199901283400401

Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411 doi: 10.1002/art.20217

Maini RN, Breedveld FC, Kalden JR et al (2004) Sustained improvement over 2 years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051–1065 doi: 10.1002/art.20159

Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523 doi: 10.1136/ard.2008.092932

Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829 doi: 10.1002/art.22033

Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997 doi: 10.1016/S0140-6736(08)60453-5

Jones G, Sebba A, Gu J et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96 doi: 10.1136/ard.2008.105197

Kremer JM, Genant HK, Moreland LW et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953–963 doi: 10.1002/art.23397

Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 54:2793–2806 doi: 10.1002/art.22025

Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123 doi: 10.1056/NEJMoa050524

Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44:714–720 doi: 10.1093/rheumatology/keh567

Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983–989 doi: 10.1136/ard.2005.043257

Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach. J Gastroenterol Hepatol 21:1366–1371 doi: 10.1111/j.1440-1746.2006.04559.x

Stone JH, Holbrook JT, Marriott MA et al (2006) Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54:1608–1618 doi: 10.1002/art.21869

Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426 doi: 10.1136/ard.2004.033993

Geborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703 doi: 10.1136/ard.2004.030528

Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602 doi: 10.1161/01.CIR.0000124490.27666.B2

Chung ES, Packer M, Lo KH, Fasanmade AA (2003) Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140 doi: 10.1161/01.CIR.0000077913.60364.D2

Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biologic agents: a double-edged sword? Autoimmun Rev 9:188–193 doi: 10.1016/j.autrev.2009.10.003

Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412 doi: 10.1002/art.21386

Curtis JR, Patkar N, Xie A et al (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. Arthritis Rheum 56:1125–1133 doi: 10.1002/art.22504

Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357 doi: 10.1007/s10165-009-0197-6

Turesson C, Jarenros A, Jacobsson L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63:952–955 doi: 10.1136/ard.2003.018101

Solomon DH, Karlson EW, RImm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307 doi: 10.1161/01.CIR.0000054612.26458.B2

Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331 doi: 10.1136/ard.2009.113696